Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
InMode Ltd. stock logo
INMD
InMode
$15.16
-0.4%
$14.33
$13.14
$19.85
$957.95M1.951.23 million shs595,953 shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$6.29
+0.9%
$6.50
$5.47
$10.14
$928.29M1.76675,108 shs319,320 shs
Nevro Corp. stock logo
NVRO
Nevro
$5.85
+0.1%
$5.85
$3.17
$10.37
$224.32M0.81800,223 shs753,602 shs
SiBone stock logo
SIBN
SiBone
$18.46
+0.2%
$17.82
$11.70
$20.05
$786.77M0.93395,377 shs288,621 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
InMode Ltd. stock logo
INMD
InMode
0.00%+6.80%+7.03%-1.59%-12.75%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.00%+5.81%-3.16%-11.35%-7.44%
Nevro Corp. stock logo
NVRO
Nevro
0.00%0.00%0.00%0.00%-32.10%
SiBone stock logo
SIBN
SiBone
0.00%+0.16%-2.33%+37.05%+42.11%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
InMode Ltd. stock logo
INMD
InMode
3.3331 of 5 stars
3.13.00.00.03.11.71.9
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.4324 of 5 stars
3.53.00.00.00.63.31.9
Nevro Corp. stock logo
NVRO
Nevro
0.1712 of 5 stars
1.00.00.00.00.01.70.6
SiBone stock logo
SIBN
SiBone
4.1495 of 5 stars
2.55.00.03.32.72.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
InMode Ltd. stock logo
INMD
InMode
2.13
Hold$18.5422.35% Upside
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.00
Buy$12.5098.89% Upside
Nevro Corp. stock logo
NVRO
Nevro
1.92
Reduce$5.36-8.29% Downside
SiBone stock logo
SIBN
SiBone
3.00
Buy$22.5021.89% Upside

Current Analyst Ratings Breakdown

Latest NVRO, INMD, MDXG, and SIBN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
SiBone stock logo
SIBN
SiBone
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00
5/6/2025
SiBone stock logo
SIBN
SiBone
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$24.00 ➝ $24.00
4/30/2025
InMode Ltd. stock logo
INMD
InMode
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$29.00 ➝ $24.00
4/29/2025
InMode Ltd. stock logo
INMD
InMode
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$19.00 ➝ $16.25
4/29/2025
InMode Ltd. stock logo
INMD
InMode
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$17.00 ➝ $15.00
4/29/2025
InMode Ltd. stock logo
INMD
InMode
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/28/2025
InMode Ltd. stock logo
INMD
InMode
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/28/2025
InMode Ltd. stock logo
INMD
InMode
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$22.00 ➝ $16.00
4/28/2025
InMode Ltd. stock logo
INMD
InMode
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/14/2025
InMode Ltd. stock logo
INMD
InMode
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$16.00 ➝ $15.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
InMode Ltd. stock logo
INMD
InMode
$394.82M2.43$1.82 per share8.31$10.12 per share1.50
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$348.88M2.66$0.33 per share19.14$1.31 per share4.80
Nevro Corp. stock logo
NVRO
Nevro
$408.52M0.55N/AN/A$8.10 per share0.72
SiBone stock logo
SIBN
SiBone
$167.18M4.71N/AN/A$3.98 per share4.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
InMode Ltd. stock logo
INMD
InMode
$181.27M$2.336.508.33N/A44.79%17.17%15.20%7/30/2025 (Estimated)
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$42.42M$0.2723.2819.64N/A11.40%22.70%16.77%7/30/2025 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)
SiBone stock logo
SIBN
SiBone
-$30.91M-$0.64N/AN/AN/A-15.03%-16.00%-11.69%8/4/2025 (Estimated)

Latest NVRO, INMD, MDXG, and SIBN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$0.06N/AN/AN/A$90.79 millionN/A
5/5/2025Q1 2025
SiBone stock logo
SIBN
SiBone
-$0.24-$0.15+$0.09-$0.15$45.13 million$47.29 million
4/30/2025Q1 2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$0.06$0.06N/A$0.05$86.32 million$88.21 million
4/28/2025Q1 2025
InMode Ltd. stock logo
INMD
InMode
$0.45$0.31-$0.14$0.26$82.21 million$77.87 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
InMode Ltd. stock logo
INMD
InMode
N/AN/AN/AN/AN/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
SiBone stock logo
SIBN
SiBone
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
InMode Ltd. stock logo
INMD
InMode
N/A
8.73
7.86
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.09
4.70
4.13
Nevro Corp. stock logo
NVRO
Nevro
0.67
5.02
3.76
SiBone stock logo
SIBN
SiBone
0.21
8.53
7.26

Institutional Ownership

CompanyInstitutional Ownership
InMode Ltd. stock logo
INMD
InMode
68.04%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
79.15%
Nevro Corp. stock logo
NVRO
Nevro
95.52%
SiBone stock logo
SIBN
SiBone
98.11%

Insider Ownership

CompanyInsider Ownership
InMode Ltd. stock logo
INMD
InMode
6.92%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
1.70%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
SiBone stock logo
SIBN
SiBone
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
InMode Ltd. stock logo
INMD
InMode
48063.21 million58.84 millionOptionable
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
870147.70 million145.19 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,09038.37 million36.27 millionOptionable
SiBone stock logo
SIBN
SiBone
35042.62 million40.95 millionOptionable

Recent News About These Companies

SI-BONE, Inc. Reports Strong Q1 2025 Growth

New MarketBeat Followers Over Time

Media Sentiment Over Time

InMode stock logo

InMode NASDAQ:INMD

$15.16 -0.06 (-0.36%)
Closing price 07/3/2025 03:31 PM Eastern
Extended Trading
$15.16 +0.01 (+0.03%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

MiMedx Group stock logo

MiMedx Group NASDAQ:MDXG

$6.28 +0.06 (+0.88%)
Closing price 07/3/2025 03:00 PM Eastern
Extended Trading
$6.16 -0.12 (-1.91%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Nevro stock logo

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)
Closing price 04/2/2025
Extended Trading
$5.85 0.00 (0.00%)
As of 04/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

SiBone stock logo

SiBone NASDAQ:SIBN

$18.46 +0.03 (+0.16%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.